liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
ANMCO Research Centre, Italy .
Campus Virchow Klinikum, Germany .
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Cardiology in Linköping.
University of Athens, Greece .
Show others and affiliations
2013 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 15, no 10, 1173-1184 p.Article in journal (Refereed) Published
Abstract [en]

To evaluate how recommendations of European guidelines regarding pharmacological and non-pharmacological treatments for heart failure (HF) are adopted in clinical practice. less thanbrgreater than less thanbrgreater thanThe ESC-HF Long-Term Registry is a prospective, observational study conducted in 211 Cardiology Centres of 21 European and Mediterranean countries, members of the European Society of Cardiology (ESC). From May 2011 to April 2013, a total of 12 440 patients were enrolled, 40.5 with acute HF and 59.5 with chronic HF. Intravenous treatments for acute HF were heterogeneously administered, irrespective of guideline recommendations. In chronic HF, with reduced EF, reninangiotensin system (RAS) blockers, beta-blockers, and mineralocorticoid antagonists (MRAs) were used in 92.2, 92.7, and 67.0 of patients, respectively. When reasons for non-adherence were considered, the real rate of undertreatment accounted for 3.2, 2.3, and 5.4 of the cases, respectively. About 30 of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them. The more relevant reasons for non-implantation of a device, when clinically indicated, were related to doctor uncertainties on the indication, patient refusal, or logistical/cost issues. less thanbrgreater than less thanbrgreater thanThis pan-European registry shows that, while in patients with acute HF, a large heterogeneity of treatments exists, drug treatment of chronic HF can be considered largely adherent to recommendations of current guidelines, when the reasons for non-adherence are taken into account. Observations regarding the real possibility to adhere fully to current guidelines in daily clinical practice should be seriously considered when clinical practice guidelines have to be written.

Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B , 2013. Vol. 15, no 10, 1173-1184 p.
Keyword [en]
Heart failure, ACE inhibitors, Beta-blockers, MRAs, ICD, CRT
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-100031DOI: 10.1093/eurjhf/hft134ISI: 000325175700013OAI: diva2:659437

Funding Agencies|ESC||Abbot Vascular||Bayer Pharma||BMS/Pfizer||Boehringer Ingelheim International||Daiichi Sankyo Europe||Menarini International||Novartis Pharma||Laboratoires Servier||Amgen||Boston Scientific International||MSD/Merck Co||Sanofi-Aventis Group||

Available from: 2013-10-25 Created: 2013-10-25 Last updated: 2013-10-25

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Division of Cardiovascular MedicineFaculty of Health SciencesDepartment of Cardiology in Linköping
In the same journal
European Journal of Heart Failure
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 49 hits
ReferencesLink to record
Permanent link

Direct link